The Week

Alpha Tau Medical (DRTS) rose 2.66% this week to close at $15.03, comfortably ahead of the S&P 500’s +0.09%, an outperformance of about 2.57 percentage points. The stock started weak: Monday (Aug 31) opened higher but slid to $14.11, and Tuesday (Sep 1) briefly touched the week’s low at $13.65 before settling at $13.96. From Wednesday it pushed higher, peaking at $15.17 on Friday (Sep 4) and closing at $15.03. Weekly amplitude was 10.35%, with average daily volume around 1.07m shares, about 78% above the 60-day median, pointing to a pickup in turnover.

Key Events

The week was anchored by the completion of enrolment in the 48-patient IMPACT pancreatic cancer Alpha DaRT pilot study, announced on Monday (Aug 31). On Wednesday (Sep 2), the company confirmed that CFO Levy would join a fireside chat at the H.C. Wainwright global investor conference. Two articles on Saturday (Sep 5) added to the narrative: one noted the stock touching a 1-year high, the other asked whether the IMPACT enrolment milestone is reshaping the investment case. No major regulatory or partnership updates appeared this week; the story was largely clinical progress plus investor communications.

Analyst Ratings

Five brokers cover the stock: three rate it buy, one overweight, and one hold, with no underweight or sell calls. The consensus rating is buy, with a consensus target of $17, roughly 13.1% above the $15.03 close. The target range is wide, from $8 to $30, reflecting real dispersion in views. Within the medical devices industry, the stock ranks 53rd out of 142 names, in the upper-middle of the group.

The Week Ahead

No company earnings are scheduled. On the macro front, the US NFIB small business optimism index lands on Tuesday (Sep 8). Thursday (Sep 10) is busier: initial jobless claims, final demand PPI and core PPI, existing home sales, wholesale sales, and the 10-year Treasury auction’s high yield and bid-to-cover ratio. For a clinical-stage medtech name, the key thing to watch is whether management follows up on the IMPACT enrolment with any signal on data readouts or timelines.

In Short

This week’s tension sits between clinical momentum and valuation divergence. The completion of IMPACT pancreatic cancer enrolment was the main company event, yet the wide $8-to-$30 target range shows how split the market remains on long-term value. Latest-session flows were mixed: smaller-size money on the bid, large-lot money on the offer. The next test is the cadence of IMPACT data and whether investor conferences bring a firmer timeline.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.